Age and height predict neuropathy risk in patients with HIV prescribed stavudine

Neurology

Volumn 73, Issue 4, 2009, Pages 315-320

  Cherry, C L ^a,f   Affandi, J S ^b   Imran, D ^c   Yunihastuti, E ^c   Smyth, K ^d   Vanar, S ^e   Kamarulzaman, A ^e   Price, P ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^d AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^e UNIVERSITY OF MALAYA   (Malaysia)

^f ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

STAVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; BODY HEIGHT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDONESIA; MAJOR CLINICAL STUDY; MALAYSIA; MALE; NEUROPATHY; ONSET AGE; PREDICTION; PRIORITY JOURNAL; SENSORY NEUROPATHY;

EID: 68249102371     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181af7a22     Document Type: Article

References (24)

1. Keswani S, Pardo C, Cherry C, Hoke A, McArthur J. HIV-associated sensory neuropathies. AIDS 2002;16:2105-2117.
2. Meyer-Rosberg K, Kvarnström A, Kinnman E, Gordh T, Nordfors L, Kristofferson A. Peripheral neuropathic pain: a multidimensional burden for patients. Eur J Pain 2001;5:379-389.
3. Smyth K, Affandi J, McArthur J, et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia, 1993-2006. HIV Med 2007;8:367-373.
4. Pettersen J, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006;59:816-824.
5. Browne M, Mayer K, Chafee S, et al. 2′,3′-didehydro-3′- deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993;167:21-29.
6. Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006;20:1163-1169.
7. Konchalard K, Wangphonpattanasiri K. Clinical and electrophysiologic evaluation of peripheral neuropathy in a group of HIV-infected patients in Thailand. J Med Assoc Thai 2007;90:774-781.
8. Forna F, Liechty C, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007;44:456-462.
9. Wright E, Brew B, Arayawichanon A, et al. Neurological disorders are prevalent in HIV positive outpatients in the Asia-Pacific Region. Neurology 2008;71:50-56.
10. UNAIDS/WHO. AIDS Epidemic Update. 2007. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS and World Health Organization. Available at: http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. Accessed June 19, 2009.
11. Cherry C, Wesselingh S, Lal L, McArthur J. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 2005;65:1778-1781.
12. Affandi J, Price P, Imran D, Yuhaningsih E, Djauzi S, Cherry C. Can we predict neuropathy risk before stavudine prescription in a resource limited setting? AIDS Res and Hum Retroviruses 2008;24:1281-1284.
13. Cherry C, Skolasky R, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006;66:867- 873.
14. Dore G, Correll P, Li Y, Kaldor J, Cooper D, Brew B. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999;13:1249-1253.
15. Watters M, Poff P, Shiramizu B, et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 2004;62:1378-1383.
16. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: The Manhattan HIV Brain Bank. Arch Neurol 2004;61:546-551.
17. Cheng Y, Gregg E, Kahn H, Williams D, De Rekeneire N, Narayan K. Peripheral insensate neuropathy: a tall problem for US adults? Am J Epidemiol 2006;164:873-880.
18. Tapp R, Shaw J, de Courten M, et al. Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med 2003;20:105-113.
19. Brinkman K, Smeitink J, Romijn J, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reversetranscriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-1115.
20. Lichtenstein K, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005;40:148-157.
21. Enting R, Hoetelmans R, Lange J, Burger D, Beijnen J, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998;12:1941-1955.
22. Capparelli E, Holland D, Okamoto C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005;19:949-952.
23. Brambilla A, Novati R, Calori G, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003;17:1993-1995.
24. Hennekens C, Buring J. Epidemiology in Medicine. Philadelphia: Lippincott Williams & Wilkins; 1987.